A Phase 2 interventional study of Daprodustat and Epoetin alfa in Anaemia, sponsored by GlaxoSmithKline. Completed at 11 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-06-03.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 11th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 2, and was the 18th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 13th largest by enrollment, is one of 4 that started in 2017, is one of 11 in phase 2, and was the 24th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This will be an open-label, randomized, parallel-group study in hemodialysis-dependent (HD) participants with anemia associated with chronic kidney disease (CKD), designed to compare the effects of daprodustat to epoetin alfa on blood pressure (BP). Participants will be screened for eligibility within 7 and 30 days prior to erythropoesis-stimulating agent (ESA) washout. Following a 2-week ESA washout period, on Day 1 participants will be randomized 1:1 and stratified by prior ESA dose before they undergo Acute Challenge 1, a single dose challenge to compare the acute effects on BP of the highest planned once-daily maintenance dose of daprodustat (24 milligrams [mg]) to the highest starting dose of epoetin alfa (100 units/kilogram [U/kg]). This will be followed by an 8-week hemoglobin (Hgb)-maintenance period, where doses of either daprodustat or epoetin alfa will be administered and adjusted. At the end of Hgb maintenance period, on Day 57 an Acute Challenge 2 will be repeated utilizing the same treatment dose administered in Acute Challenge 1; there will be a follow-up visit within 14+/-3 days after completing treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive a single dose of 100 U/kg epoetin alfa IV. After completing Acute Challenge 1, participants will enter in an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
Drug: Epoetin alfa
On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive 24 mg daprodustat. After completing Acute Challenge 1, participants will enter an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
Drug: Daprodustat
Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.
Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57
The effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM after 8 weeks of Hgb maintenace therapy on Day 57. Analysis was based on "analysis of covariance (ANCOVA) with terms for treatment, prior erythropoiesis-stimulating agent (ESA) dose (low/high), post-Hemodialysis dependent (HD)/pre-AC 1 SBP, difference between post-HD/pre-AC 2 SBP and post-HD/pre-AC 1 SBP and treatment by difference in post-HD SBP between AC 1 and 2 interaction." Least square (LS) mean of 6 hour average SBP post AC2 on Day 57 and its corresponding standard error has been presented.
Time frame: Up to 6 hours post dose on Day 57
Average of SBP, Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) Measured by ABPM Over 6-hour Post Dosing on Day 1
The initial effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM over 6 hour post-dosing on Day 1. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 SBP, DBP and MAP. LS mean of 6 hour average SBP, DBP and MAP post AC1 on Day 1 and its corresponding standard error has been presented.
Time frame: Up to 6 hours post dose on Day 1
Average of Heart Rate (HR) Measured by ABPM Over 6 Hour Post Dosing on Day 1
The initial effect of daprodustat and epoetin alfa on HR was compared using ABPM over 6 hour post-dosing on Day 1. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 HR. LS mean of 6 hour average HR post AC1 on Day 1 and its corresponding standard error has been presented.
Time frame: Up to 6 hours post dose on Day 1
Area Under the Effect Curve (AUEC) of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 1
The initial effect of daprodustat and epoetin alfa on blood pressure was compared using AUEC of SBP, DBP and MAP measured by ABPM over 24-hour post dosing on Day 1. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hours post dose on Day 1 and its corresponding standard error has been presented.
Time frame: Up to 24 hours post dose on Day 1
AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 1
The initial effect of daprodustat and epoetin alfa on HR was compared using AUEC of HR measured by ABPM over 24-hour post dosing. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hours post dose on Day 1 and its corresponding standard error has been presented.
Time frame: Up to 24 hours post dose on Day 1
Average of DBP and MAP Measured by ABPM Over 6-hour Post Dosing on Day 57
The effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM over 6 hour post-dosing after AC2 on Day 57. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 DBP and MAP, difference between post-HD/pre-AC2 DBP and MAP and post-HD/pre-AC1 DBP and MAP and treatment by difference in post-HD DBP and MAP between AC1 and 2 interaction. LS mean of 6 hour average DBP and MAP post AC2 on Day 57 and its corresponding standard error has been presented.
Time frame: Up to 6 hours post dose on Day 57
Average of HR Measured by ABPM Over 6 Hour Post Dosing on Day 57
The effect of daprodustat and epoetin alfa on HR was compared using ABPM over 6 hour post-dosing. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 HR, difference between post-HD/pre-AC2 HR and post-HD/pre-AC1 HR and treatment by difference in post-HD HR between AC1 and 2 interaction. LS mean of 6 hour average HR post AC2 on Day 57 and its corresponding standard error has been presented.
Time frame: Up to 6 hours post dose on Day 57
AUEC of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 57
The effect of daprodustat and epoetin alfa on blood pressure was compared using AUEC of SBP, DBP and MAP measured by ABPM over 24-hour post dosing on Day 57. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hour post dose on Day 57 and its corresponding standard error has been presented.
Time frame: Up to 24 hours post dose on Day 57
AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 57
The effect of daprodustat and epoetin alfa on HR was compared using AUEC of HR measured by ABPM over 24-hour post dosing on Day 57. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hour post dose on Day 57 and its corresponding standard error has been presented.
Time frame: Up to 24 hours post dose on Day 57
Change From Pre-dose in SBP, DBP and MAP at Day 1
The change from pre-dose in SBP, DBP and MAP was measured using ABPM to compare the initial effect of daprodustat to epoetin alfa after AC1 on Day 1. Change from pre-dose at each timepoint is calculated as measurement at post-dose minus pre-acute challenge 1 measurement.
Time frame: Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 hours post-dose
Change From Pre-dose in HR at Day 1
The change from pre-dose in HR was measured using ABPM to compare the initial effect of daprodustat to epoetin alfa after AC1 on Day 1. Change from pre-dose at each timepoint is calculated as measurement at post-dose minus pre-acute challenge 1 measurement.
Time frame: Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 hours post-dose
Plasma Concentrations of Daprodustat
Blood samples were collected at indicated time points for the concentrations of daprodustat.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Plasma Concentrations of Metabolite GSK2391220
Blood samples were collected at indicated time points for the concentrations of metabolite GSK2391220.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Plasma Concentrations of Metabolite GSK2506104
Blood samples were collected at indicated time points for the concentrations of metabolite GSK2506104.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Plasma Concentrations of Metabolite GSK2487818
Blood samples were collected at indicated time points for the concentrations of metabolite GSK2487818.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Plasma Concentrations of Metabolite GSK2506102
Blood samples were collected at indicated time points for the concentrations of metabolite GSK25206102.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Plasma Concentrations of Metabolite GSK2531398
Blood samples were collected at indicated time points for the concentrations of metabolite GSK2531398.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Plasma Concentrations of Metabolite GSK2531401
Blood samples were collected at indicated time points for the concentrations of metabolite GSK2531401.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Maximum Plasma Concentration (Cmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Time of Occurrence of Cmax (Tmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Terminal Phase Half-life (t1/2) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Area Under Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.
Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Number of Participants With Any Serious Adverse Events (SAEs)
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.
Time frame: Up to Week 10
Number of Participants With Treatment Emergent Common (>=2%) Non-serious Adverse Events (Non-SAEs)
An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Number of participants with treatment emergent common (\>=2% non-SAEs in each arm) non-SAEs has been presented.
Time frame: Up to Week 8
Number of Participants Who Discontinued the Study Treatment
Number of participants who discontinued the study treatment due to any reason are presented. The reasons for discontinuation included adverse events, protocol specified withdrawal criteria met, physician decision and withdrawal by participant.
Time frame: Up to Week 10
Absolute Values for Clinical Chemistry Parameters: Albumin and Protein
Blood samples were collected for the analysis of clinical chemistry parameters including albumin and protein. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)
Blood samples were collected for the analysis of clinical chemistry parameters including ALP, ALT and AST. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Indirect (Indrt) Bilirubin
Blood samples were collected for the analysis of clinical chemistry parameters including direct bilirubin, total bilirubin and Indrt bilirubin. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Clinical Chemistry Parameters: Calcium Corrected for Albumin (CCA), Glucose, Potassium, Phosphate and Sodium
Blood samples were collected for the analysis of clinical chemistry parameters including CCA, glucose, potassium, phosphate and sodium. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Clinical Chemistry Parameters: Albumin and Protein
Blood samples were collected for the analysis of clinical chemistry parameters including albumin and protein. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Clinical Chemistry Parameters: ALP, ALT and AST
Blood samples were collected for the analysis of clinical chemistry parameters including ALP, ALT and AST. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Indrt. Bilirubin
Blood samples were collected for the analysis of clinical chemistry parameters including direct bilirubin, total bilirubin and indrt. bilirubin. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Clinical Chemistry Parameters: CCA, Glucose, Potassium, Phosphate and Sodium
Blood samples were collected for the analysis of clinical chemistry parameters including CCA, glucose, potassium, phosphate and sodium. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
Blood samples were collected for the analysis of hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Hematology Parameter: Hematocrit
Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Hematology Parameters: Erythrocytes and Reticulocytes
Blood samples were collected for the analysis of hematology parameters: erythrocytes and reticulocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Hematology Parameters: Hemoglobin and Erythrocyte Mean Corpusclar Hemoglobin Concentration ( Ery. MCHC)
Blood samples were collected for the analysis of hematology parameters: hemoglobin and ery.MCHC. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Hematology Parameter: Ery. Mean Corpuscular Hemoglobin (MCH) and Reticulocyte Corpuscular Hemoglobin Content (CHr)
Blood samples were collected for the analysis of hematology parameter: ery.MCH and CHr. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Hematology Parameter: Ery. Mean Corpuscular Volume (MCV)
Blood samples were collected for the analysis of hematology parameter: ery.MCV. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Hematology Parameter: Erythrocyte Distribution Width
Blood samples were collected for the analysis of hematology parameter: erythrocyte distribution width. Baseline value (Day1) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
Blood samples were collected for the analysis of hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Hematology Parameter: Hematocrit
Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Hematology Parameters: Erythrocytes and Reticulocytes
Blood samples were collected for the analysis of hematology parameters: erythrocytes and reticulocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Hematology Parameters: Hemoglobin and Ery. MCHC
Blood samples were collected for the analysis of hematology parameters: hemoglobin and ery.MCHC. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Hematology Parameters: Ery. MCH and CHr
Blood samples were collected for the analysis of hematology parameter: ery.MCH and CHr. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Hematology Parameter: Ery. MCV
Blood samples were collected for the analysis of hematology parameter: ery.MCV. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Change From Baseline Values for Hematology Parameter: Erythrocyte Distribution Width
Blood samples were collected for the analysis of hematology parameter: erythrocyte distribution width. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10
Absolute Values for Electrocardiogram (ECG) Mean Heart Rate
Full 12-lead ECGs were obtained in supine position using an ECG machine to measure mean heart rate. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10
Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval Corrected for Heart Rate (QTc) and QT Interval Corrected for Heart Rate Using Bazett's Formula (QTcB)
Full 12-lead ECGs were obtained in supine position using an ECG machine to measure ECG parameters: PR interval, QRS duration, QTc interval and QTcB. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10
Change From Baseline Values for ECG Mean Heart Rate
Full 12-lead ECGs were obtained in supine position using an ECG machine to measure mean heart rate. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10
Change From Baseline Values for ECG Parameters: PR Interval, QRS Duration, QTc and QTcB
Full 12-lead ECGs were obtained in supine position using an ECG machine to measure ECG parameters: PR interval, QRS duration, QTc interval and QTcB. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10
Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Vital signs including SBP and DBP were measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Absolute Values for Temperature
Temperature was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Absolute Values for Pulse Rate
Pulse rate was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.
Time frame: Baseline (Day 1, predose) and at Day 1:3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Change From Baseline Values for Vital Signs: SBP and DBP
Vital signs including SBP and DBP were measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Change From Baseline Values for Temperature
Temperature was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Change From Baseline Values for Pulse Rate
Pulse rate was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
This was a randomized, open label study that evaluated the effect of daprodustat on blood pressure in participants with anemia associated with chronic kidney disease on hemodialysis switched from a stable dose of an erythropoiesis-stimulating agent.
| Milestone | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Started | 45 | 43 |
| Completed | 45 | 43 |
| Not completed | 0 | 0 |
| Milestone | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Started | 45 | 43 |
| Completed | 32 | 36 |
| Not completed | 13 | 7 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Protocol-specified withdrawal criterion | 7 | 4 |
| Withdrew: Adverse event | 2 | 2 |
| Milestone | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Started | 32 | 36 |
| Completed | 32 | 36 |
| Not completed | 0 | 0 |
| Milestone | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Started | 32 | 36 |
| Completed | 32 | 36 |
| Not completed | 0 | 0 |
The effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM after 8 weeks of Hgb maintenace therapy on Day 57. Analysis was based on "analysis of covariance (ANCOVA) with terms for treatment, prior erythropoiesis-stimulating agent (ESA) dose (low/high), post-Hemodialysis dependent (HD)/pre-AC 1 SBP, difference between post-HD/pre-AC 2 SBP and post-HD/pre-AC 1 SBP and treatment by difference in post-HD SBP between AC 1 and 2 interaction." Least square (LS) mean of 6 hour average SBP post AC2 on Day 57 and its corresponding standard error has been presented.
| Millimeters of mercury (mmHg) | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57 | 142.87 ± 3.039 | 143.03 ± 2.995 |
The initial effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM over 6 hour post-dosing on Day 1. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 SBP, DBP and MAP. LS mean of 6 hour average SBP, DBP and MAP post AC1 on Day 1 and its corresponding standard error has been presented.
| mmHg | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| SBP | 141.36 ± 3.115 | 142.68 ± 3.313 |
| DBP | 75.97 ± 1.253 | 77.92 ± 1.332 |
| MAP | 99.18 ± 2.212 | 101.58 ± 2.351 |
The initial effect of daprodustat and epoetin alfa on HR was compared using ABPM over 6 hour post-dosing on Day 1. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 HR. LS mean of 6 hour average HR post AC1 on Day 1 and its corresponding standard error has been presented.
| Beats per minute | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Average of Heart Rate (HR) Measured by ABPM Over 6 Hour Post Dosing on Day 1 | 70.77 ± 1.416 | 73.72 ± 1.507 |
The initial effect of daprodustat and epoetin alfa on blood pressure was compared using AUEC of SBP, DBP and MAP measured by ABPM over 24-hour post dosing on Day 1. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hours post dose on Day 1 and its corresponding standard error has been presented.
| mmHg*Hours | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| AUEC of SBP | 3337.91 ± 84.144 | 3351.33 ± 90.217 |
| AUEC of DBP | 1763.11 ± 39.814 | 1834.82 ± 42.688 |
| AUEC of MAP | 2324.69 ± 57.517 | 2378.93 ± 61.668 |
The initial effect of daprodustat and epoetin alfa on HR was compared using AUEC of HR measured by ABPM over 24-hour post dosing. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hours post dose on Day 1 and its corresponding standard error has been presented.
| Beats per minute*Hours | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 1 | 1652.63 ± 35.152 | 1727.03 ± 37.690 |
The effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM over 6 hour post-dosing after AC2 on Day 57. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 DBP and MAP, difference between post-HD/pre-AC2 DBP and MAP and post-HD/pre-AC1 DBP and MAP and treatment by difference in post-HD DBP and MAP between AC1 and 2 interaction. LS mean of 6 hour average DBP and MAP post AC2 on Day 57 and its corresponding standard error has been presented.
| mmHg | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| DBP | 75.58 ± 1.465 | 77.64 ± 1.436 |
| MAP | 98.98 ± 2.208 | 101.49 ± 2.169 |
The effect of daprodustat and epoetin alfa on HR was compared using ABPM over 6 hour post-dosing. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 HR, difference between post-HD/pre-AC2 HR and post-HD/pre-AC1 HR and treatment by difference in post-HD HR between AC1 and 2 interaction. LS mean of 6 hour average HR post AC2 on Day 57 and its corresponding standard error has been presented.
| Beats per minute | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Average of HR Measured by ABPM Over 6 Hour Post Dosing on Day 57 | 70.49 ± 1.146 | 70.62 ± 1.125 |
The effect of daprodustat and epoetin alfa on blood pressure was compared using AUEC of SBP, DBP and MAP measured by ABPM over 24-hour post dosing on Day 57. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hour post dose on Day 57 and its corresponding standard error has been presented.
| mmHg*Hours | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| AUEC of SBP | 3288.43 ± 85.805 | 3433.40 ± 91.786 |
| AUEC of DBP | 1736.11 ± 38.659 | 1853.60 ± 41.354 |
| AUEC of MAP | 2299.42 ± 58.712 | 2431.36 ± 62.804 |
The effect of daprodustat and epoetin alfa on HR was compared using AUEC of HR measured by ABPM over 24-hour post dosing on Day 57. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hour post dose on Day 57 and its corresponding standard error has been presented.
| Beats per minute*Hours | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 57 | 1579.38 ± 40.886 | 1677.06 ± 43.736 |
The change from pre-dose in SBP, DBP and MAP was measured using ABPM to compare the initial effect of daprodustat to epoetin alfa after AC1 on Day 1. Change from pre-dose at each timepoint is calculated as measurement at post-dose minus pre-acute challenge 1 measurement.
| mmHg | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| SBP, Hour 1, n=34, 31 | 1.00 ± 17.178 | 5.27 ± 20.471 |
| SBP, Hour 2, n=35, 31 | -4.99 ± 28.170 | 4.72 ± 22.651 |
| SBP, Hour 3, n=35, 31 | -5.85 ± 29.636 | 5.09 ± 21.163 |
| SBP, Hour 4, n=35, 31 | -1.68 ± 26.000 | 0.93 ± 23.962 |
| SBP, Hour 5, n=35, 31 | -1.86 ± 29.171 | -2.10 ± 23.849 |
| SBP, Hour 6, n=35, 31 | 0.29 ± 31.903 | -2.54 ± 28.908 |
| SBP, Hour 7, n=34, 26 | 2.30 ± 33.896 | 0.63 ± 19.016 |
| SBP, Hour 8, n=33, 29 | 0.43 ± 31.418 | 3.83 ± 20.723 |
| SBP, Hour 9, n=33, 30 | -5.81 ± 30.725 | 0.25 ± 26.294 |
| SBP, Hour 10, n=31, 28 | -5.70 ± 28.018 | 1.48 ± 25.952 |
| SBP, Hour 11, n=33, 27 | -7.00 ± 27.529 | 1.96 ± 24.421 |
| SBP, Hour 12, n=35, 28 | -6.05 ± 29.932 | -1.67 ± 19.380 |
| SBP, Hour 13, n=34, 28 | -2.49 ± 25.319 | -1.37 ± 25.596 |
| SBP, Hour 14, n=34, 31 | -5.30 ± 30.030 | 4.57 ± 29.767 |
| SBP, Hour 15, n=32, 26 | -1.47 ± 33.573 | -0.13 ± 24.287 |
| SBP, Hour 16, n=34, 31 | -4.40 ± 30.990 | 8.59 ± 24.729 |
| SBP, Hour 17, n=32, 30 | -5.05 ± 29.795 | 1.76 ± 23.896 |
| SBP, Hour 18, n=32, 27 | -5.23 ± 25.993 | 5.48 ± 23.330 |
| SBP, Hour 19, n=34, 27 | -3.01 ± 24.230 | 1.52 ± 21.072 |
| SBP, Hour 20, n=33, 27 | -13.27 ± 24.138 | 6.89 ± 16.834 |
| SBP, Hour 21, n=30, 27 | -8.32 ± 26.003 | 1.72 ± 26.777 |
| SBP, Hour 22, n=29, 27 | -3.93 ± 26.106 | 3.50 ± 24.428 |
| SBP, Hour 23, n=31, 26 | 2.73 ± 28.343 | 8.72 ± 24.868 |
| SBP, Hour 24, n=31, 27 | 2.63 ± 29.379 | 5.02 ± 26.601 |
| DBP, Hour 1, n=34, 31 | 0.01 ± 9.317 | 0.99 ± 13.110 |
| DBP, Hour 2, n=35, 31 | -0.82 ± 15.399 | 1.97 ± 11.986 |
| DBP, Hour 3, n=35, 31 | -1.30 ± 14.660 | 0.88 ± 11.858 |
| DBP, Hour 4, n=35, 31 | -1.06 ± 14.552 | -1.17 ± 13.621 |
| DBP, Hour 5, n=35, 31 | -0.69 ± 16.618 | -1.49 ± 11.684 |
| DBP, Hour 6, n=35, 31 | -0.06 ± 14.799 | -1.49 ± 14.457 |
| DBP, Hour 7, n=34, 26 | -0.12 ± 16.324 | -1.27 ± 15.272 |
| DBP, Hour 8, n=33, 29 | 1.35 ± 15.900 | 1.79 ± 15.178 |
| DBP, Hour 9, n=33, 30 | -2.14 ± 15.188 | -0.68 ± 11.874 |
| DBP, Hour 10, n=31, 28 | -3.52 ± 14.246 | -0.82 ± 12.802 |
| DBP, Hour 11, n=33, 27 | -4.88 ± 14.691 | -2.45 ± 10.987 |
| DBP, Hour 12, n=35, 28 | -4.79 ± 14.561 | -3.95 ± 10.718 |
| DBP, Hour 13, n=34, 28 | -2.15 ± 15.185 | -2.65 ± 12.841 |
| DBP, Hour 14, n=34, 31 | -3.99 ± 14.153 | -1.00 ± 14.759 |
| DBP, Hour 15, n=32, 26 | -0.54 ± 19.203 | -4.12 ± 13.905 |
| DBP, Hour 16, n=34, 31 | -3.56 ± 15.615 | 1.15 ± 14.186 |
| DBP, Hour 17, n=32, 30 | -3.65 ± 14.949 | -2.98 ± 13.732 |
| DBP, Hour 18, n=32, 27 | -2.08 ± 17.015 | 0.30 ± 14.219 |
| DBP, Hour 19, n=34, 27 | -0.36 ± 19.650 | -0.43 ± 14.965 |
| DBP, Hour 20, n=33, 27 | -2.96 ± 15.579 | 0.40 ± 14.501 |
| DBP, Hour 21, n=30, 27 | -2.54 ± 15.246 | 1.90 ± 15.507 |
| DBP, Hour 22, n=29, 27 | -0.25 ± 15.037 | -1.96 ± 12.058 |
| DBP, Hour 23, n=31, 26 | 4.05 ± 19.055 | -0.44 ± 13.218 |
| DBP, Hour 24, n=31, 27 | 4.48 ± 18.097 | 2.16 ± 15.124 |
| MAP, Hour 1, n=34, 31 | -1.87 ± 15.252 | 2.83 ± 19.439 |
| MAP, Hour 2, n=35, 31 | -4.79 ± 24.742 | 4.20 ± 17.890 |
| MAP, Hour 3, n=35, 31 | -5.13 ± 22.342 | 3.46 ± 14.940 |
| MAP, Hour 4, n=35, 31 | -4.78 ± 23.640 | -1.05 ± 17.552 |
| MAP, Hour 5, n=35, 31 | -3.48 ± 26.458 | -1.18 ± 16.235 |
| MAP, Hour 6, n=35, 31 | -1.27 ± 25.359 | -2.17 ± 19.573 |
| MAP, Hour 7, n=34, 26 | 0.45 ± 28.445 | 0.87 ± 18.659 |
| MAP, Hour 8, n=33, 29 | 0.08 ± 27.487 | 2.20 ± 17.002 |
| MAP, Hour 9, n=33, 30 | -7.02 ± 24.498 | 0.61 ± 17.072 |
| MAP, Hour 10, n=31, 28 | -8.18 ± 24.057 | 0.76 ± 18.604 |
| MAP, Hour 11, n=33, 27 | -8.74 ± 25.719 | -3.60 ± 19.022 |
| MAP, Hour 12, n=35, 28 | -6.49 ± 26.669 | -6.15 ± 16.336 |
| MAP, Hour 13, n=34, 28 | -5.72 ± 23.609 | -3.32 ± 17.660 |
| MAP, Hour 14, n=34, 31 | -6.99 ± 25.710 | -0.75 ± 17.024 |
| MAP, Hour 15, n=32, 26 | -4.06 ± 27.693 | -5.10 ± 19.458 |
| MAP, Hour 16, n=34, 31 | -4.79 ± 26.805 | 3.84 ± 22.886 |
| MAP, Hour 17, n=32, 30 | -5.10 ± 25.873 | -2.09 ± 19.856 |
| MAP, Hour 18, n=32, 27 | -6.98 ± 24.790 | 1.52 ± 18.745 |
| MAP, Hour 19, n=34, 27 | -4.44 ± 26.186 | -1.02 ± 17.275 |
| MAP, Hour 20, n=33, 27 | -9.47 ± 23.186 | 4.23 ± 16.311 |
| MAP, Hour 21, n=30, 27 | -7.39 ± 22.611 | 3.87 ± 20.860 |
| MAP, Hour 22, n=29, 27 | -2.77 ± 21.938 | 0.75 ± 16.888 |
| MAP, Hour 23, n=31, 26 | 0.88 ± 27.381 | 4.10 ± 18.818 |
| MAP, Hour 24, n=31, 27 | 2.02 ± 26.253 | 2.20 ± 19.276 |
The change from pre-dose in HR was measured using ABPM to compare the initial effect of daprodustat to epoetin alfa after AC1 on Day 1. Change from pre-dose at each timepoint is calculated as measurement at post-dose minus pre-acute challenge 1 measurement.
| Beats per minute | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Hour 1, n=34, 31 | -1.16 ± 9.283 | 0.13 ± 15.465 |
| Hour 2, n=35, 31 | -1.05 ± 17.259 | -2.06 ± 15.409 |
| Hour 3, n=35, 31 | 0.76 ± 15.920 | -0.16 ± 14.911 |
| Hour 4, n=35, 31 | 3.18 ± 12.717 | -1.13 ± 17.798 |
| Hour 5, n=35, 31 | 0.91 ± 13.782 | -0.66 ± 14.119 |
| Hour 6, n=35, 31 | 0.97 ± 14.763 | -1.66 ± 13.023 |
| Hour 7, n=34, 26 | 2.14 ± 13.620 | -1.01 ± 11.592 |
| Hour 8, n=33, 29 | 0.62 ± 13.326 | -1.11 ± 18.376 |
| Hour 9, n=33, 30 | 0.20 ± 14.533 | 0.67 ± 15.411 |
| Hour 10, n=31, 28 | 2.54 ± 13.575 | 1.60 ± 13.612 |
| Hour 11, n=33, 27 | 2.07 ± 14.247 | 1.57 ± 14.132 |
| Hour 12, n=35, 28 | 0.77 ± 12.386 | -2.01 ± 14.767 |
| Hour 13, n=34, 28 | -0.25 ± 12.895 | -2.45 ± 14.861 |
| Hour 14, n=34, 31 | -1.54 ± 13.148 | 0.25 ± 13.020 |
| Hour 15, n=32, 26 | -0.92 ± 13.406 | -3.06 ± 13.156 |
| Hour 16, n=34, 31 | -1.02 ± 14.018 | -2.87 ± 11.762 |
| Hour 17, n=32, 30 | -0.85 ± 14.631 | -4.34 ± 13.284 |
| Hour 18, n=32, 27 | 0.60 ± 15.553 | 0.98 ± 11.443 |
| Hour 19, n=34, 27 | -0.56 ± 14.407 | -2.65 ± 13.220 |
| Hour 20, n=33, 27 | -1.91 ± 13.956 | -4.77 ± 17.083 |
| Hour 21, n=30, 27 | -1.82 ± 13.841 | -3.00 ± 13.342 |
| Hour 22, n=29, 27 | 0.82 ± 11.686 | -2.61 ± 13.292 |
| Hour 23, n=31, 26 | -1.01 ± 12.697 | 0.24 ± 13.148 |
| Hour 24, n=31, 27 | -0.89 ± 17.530 | -0.96 ± 14.651 |
Blood samples were collected at indicated time points for the concentrations of daprodustat.
| Nanograms per milliliter | Daprodustat |
|---|---|
| Day 1, Predose, n=45 | 0.000 ± 0.000 |
| Day 1, 0.5 hours, n=43 | 197.118 ± 329.0251 |
| Day 1, 1 hour, n=43 | 265.828 ± 340.7690 |
| Day 1, 2 hours, n=43 | 156.103 ± 150.4148 |
| Day 1, 3 hours, n=43 | 114.485 ± 139.8114 |
| Day 1, 4 hours, n=44 | 105.375 ± 150.0982 |
| Day 1, 6 hours, n=44 | 71.995 ± 104.2462 |
| Day 1, 8 hours, n=43 | 50.069 ± 91.2574 |
| Day 1, 12 hours, n=41 | 14.165 ± 30.2719 |
| Day 1, 16 hours, n=43 | 5.350 ± 11.0233 |
| Day 1, 24 hours, n=43 | 2.899 ± 10.8052 |
| Day 57, Predose, n=31 | 8.657 ± 21.3825 |
| Day 57, 0.5 hours, n=31 | 175.616 ± 257.3578 |
| Day 57, 1 hour, n=31 | 260.817 ± 307.2242 |
| Day 57, 2 hours, n=30 | 245.277 ± 251.2676 |
| Day 57, 3 hours, n=31 | 142.366 ± 154.9041 |
| Day 57, 4 hours, n=32 | 82.696 ± 104.8654 |
| Day 57, 6 hours, n=31 | 43.751 ± 55.8532 |
| Day 57, 8 hours, n=31 | 16.484 ± 27.2733 |
| Day 57, 12 hours, n=30 | 8.661 ± 16.8915 |
| Day 57, 16 hours, n=30 | 7.279 ± 21.2784 |
| Day 57, 24 hours, n=31 | 1.371 ± 2.0177 |
Blood samples were collected at indicated time points for the concentrations of metabolite GSK2391220.
| Nanograms per milliliter | Daprodustat |
|---|---|
| Day 1, Predose, n=45 | 0.000 ± 0.000 |
| Day 1, 0.5 hours, n=43 | 9.847 ± NA |
| Day 1, 1 hour, n=43 | 14.361 ± 21.6405 |
| Day 1, 2 hours, n=43 | 30.036 ± 29.6152 |
| Day 1, 3 hours, n=44 | 32.359 ± 28.6734 |
| Day 1, 4 hours, n=43 | 32.892 ± 27.2772 |
| Day 1, 6 hours, n=43 | 33.105 ± 20.9136 |
| Day 1, 8 hours, n=42 | 32.267 ± 16.3824 |
| Day 1, 12 hours, n=40 | 23.921 ± 15.1007 |
| Day 1, 16 hours, n=42 | 19.771 ± 13.5013 |
| Day 1, 24 hours, n=42 | 12.693 ± 10.1135 |
| Day 57, Predose, n=31 | 3.019 ± 4.2327 |
| Day 57, 0.5 hours, n=31 | 10.043 ± 12.5832 |
| Day 57, 1 hour, n=31 | 12.410 ± 13.3576 |
| Day 57, 2 hours, n=30 | 23.433 ± 21.4154 |
| Day 57, 3 hours, n=31 | 32.861 ± 26.3829 |
| Day 57, 4 hours, n=32 | 38.443 ± 27.9354 |
| Day 57, 6 hours, n=31 | 41.432 ± 24.2976 |
| Day 57, 8 hours, n=31 | 33.689 ± 20.3669 |
| Day 57, 12 hours, n=31 | 25.771 ± 17.8554 |
| Day 57, 16 hours, n=31 | 21.481 ± 15.6404 |
| Day 57, 24 hours, n=32 | 14.836 ± 11.2824 |
Blood samples were collected at indicated time points for the concentrations of metabolite GSK2506104.
| Nanograms per milliliter | Daprodustat |
|---|---|
| Day 1, Predose, n=45 | 0.000 ± 0.000 |
| Day 1, 0.5 hours, n=43 | 9.337 ± NA |
| Day 1, 1 hour, n=43 | 13.263 ± 20.5510 |
| Day 1, 2 hours, n=43 | 28.986 ± 28.4324 |
| Day 1, 3 hours, n=44 | 32.623 ± 29.1622 |
| Day 1, 4 hours, n=43 | 34.266 ± 27.5021 |
| Day 1, 6 hours, n=43 | 37.250 ± 21.9404 |
| Day 1, 8 hours, n=42 | 39.463 ± 17.2013 |
| Day 1, 12 hours, n=40 | 33.822 ± 16.6962 |
| Day 1, 16 hours, n=42 | 31.224 ± 16.3048 |
| Day 1, 24 hours, n=42 | 24.268 ± 14.2298 |
| Day 57, Predose, n=31 | 4.133 ± 4.5315 |
| Day 57, 0.5 hours, n=31 | 10.759 ± 11.6369 |
| Day 57, 1 hour, n=31 | 12.902 ± 12.5068 |
| Day 57, 2 hours, n=30 | 23.391 ± 20.1627 |
| Day 57, 3 hours, n=31 | 33.561 ± 26.4516 |
| Day 57, 4 hours, n=32 | 41.089 ± 28.8815 |
| Day 57, 6 hours, n=31 | 47.511 ± 25.5686 |
| Day 57, 8 hours, n=31 | 43.646 ± 22.0075 |
| Day 57, 12 hours, n=31 | 39.685 ± 23.4732 |
| Day 57, 16 hours, n=31 | 36.234 ± 22.1830 |
| Day 57, 24 hours, n=32 | 27.808 ± 14.8739 |
Blood samples were collected at indicated time points for the concentrations of metabolite GSK2487818.
| Nanograms per milliliter | Daprodustat |
|---|---|
| Day 1, Predose, n=45 | 0.000 ± 0.000 |
| Day 1, 0.5 hours, n=43 | 8.624 ± NA |
| Day 1, 1 hour, n=43 | 13.181 ± 19.2280 |
| Day 1, 2 hours, n=43 | 25.204 ± 24.8233 |
| Day 1, 3 hours, n=44 | 23.632 ± 21.0661 |
| Day 1, 4 hours, n=43 | 20.726 ± 17.9713 |
| Day 1, 6 hours, n=43 | 15.509 ± 10.4545 |
| Day 1, 8 hours, n=42 | 11.654 ± 9.1747 |
| Day 1, 12 hours, n=39 | 5.673 ± 6.4670 |
| Day 1, 16 hours, n=43 | 3.298 ± 4.6779 |
| Day 1, 24 hours, n=43 | 1.379 ± 2.1969 |
| Day 57, Predose, n=31 | 1.503 ± NA |
| Day 57, 0.5 hours, n=31 | 7.760 ± 12.2768 |
| Day 57, 1 hour, n=31 | 10.507 ± 13.6474 |
| Day 57, 2 hours, n=30 | 20.254 ± 20.1125 |
| Day 57, 3 hours, n=30 | 25.092 ± 20.7688 |
| Day 57, 4 hours, n=32 | 24.865 ± 18.7941 |
| Day 57, 6 hours, n=31 | 21.749 ± 16.6572 |
| Day 57, 8 hours, n=31 | 11.419 ± 11.2821 |
| Day 57, 12 hours, n=31 | 5.537 ± 9.1160 |
| Day 57, 16 hours, n=30 | 3.613 ± 6.4974 |
| Day 57, 24 hours, n=31 | 1.693 ± 2.9455 |
Blood samples were collected at indicated time points for the concentrations of metabolite GSK25206102.
| Nanograms per milliliter | Daprodustat |
|---|---|
| Day 1, Predose, n=45 | 0.000 ± 0.000 |
| Day 1, 0.5 hours, n=43 | 1.862 ± NA |
| Day 1, 1 hour, n=44 | 2.575 ± NA |
| Day 1, 2 hours, n=43 | 5.999 ± 5.9281 |
| Day 1, 3 hours, n=44 | 7.047 ± 6.3772 |
| Day 1, 4 hours, n=43 | 7.554 ± 6.0767 |
| Day 1, 6 hours, n=43 | 8.564 ± 5.0888 |
| Day 1, 8 hours, n=42 | 9.379 ± 3.9554 |
| Day 1, 12 hours, n=40 | 8.658 ± 3.6930 |
| Day 1, 16 hours, n=42 | 8.225 ± 3.7400 |
| Day 1, 24 hours, n=42 | 7.024 ± 3.5347 |
| Day 57, Predose, n=31 | 1.126 ± 1.0181 |
| Day 57, 0.5 hours, n=30 | 2.472 ± 2.2298 |
| Day 57, 1 hour, n=31 | 2.890 ± 2.4847 |
| Day 57, 2 hours, n=30 | 5.082 ± 4.1937 |
| Day 57, 3 hours, n=31 | 7.688 ± 5.7677 |
| Day 57, 4 hours, n=32 | 9.474 ± 6.3929 |
| Day 57, 6 hours, n=30 | 11.507 ± 5.3600 |
| Day 57, 8 hours, n=31 | 10.945 ± 4.9425 |
| Day 57, 12 hours, n=31 | 10.286 ± 5.1703 |
| Day 57, 16 hours, n=31 | 9.735 ± 5.1306 |
| Day 57, 24 hours, n=32 | 8.449 ± 3.7371 |
Blood samples were collected at indicated time points for the concentrations of metabolite GSK2531398.
| Nanograms per milliliter | Daprodustat |
|---|---|
| Day 1, Predose, n=45 | 0.000 ± 0.000 |
| Day 1, 0.5 hours, n=43 | 4.409 ± NA |
| Day 1, 1 hour, n=44 | 6.139 ± NA |
| Day 1, 2 hours, n=43 | 13.779 ± 13.5109 |
| Day 1, 3 hours, n=44 | 15.087 ± 13.4427 |
| Day 1, 4 hours, n=43 | 14.881 ± 12.5678 |
| Day 1, 6 hours, n=43 | 14.907 ± 9.6957 |
| Day 1, 8 hours, n=42 | 13.930 ± 7.4098 |
| Day 1, 12 hours, n=40 | 9.784 ± 6.6328 |
| Day 1, 16 hours, n=42 | 7.751 ± 5.9158 |
| Day 1, 24 hours, n=42 | 4.687 ± 4.1099 |
| Day 57, Predose, n=31 | 1.246 ± 1.9695 |
| Day 57, 0.5 hours, n=30 | 4.482 ± 5.7104 |
| Day 57, 1 hour, n=31 | 5.406 ± 5.8321 |
| Day 57, 2 hours, n=30 | 10.580 ± 10.1185 |
| Day 57, 3 hours, n=31 | 15.191 ± 12.9991 |
| Day 57, 4 hours, n=32 | 17.904 ± 13.4024 |
| Day 57, 6 hours, n=30 | 19.827 ± 11.4600 |
| Day 57, 8 hours, n=31 | 15.038 ± 11.0475 |
| Day 57, 12 hours, n=31 | 10.292 ± 8.2309 |
| Day 57, 16 hours, n=31 | 8.348 ± 7.1590 |
| Day 57, 24 hours, n=32 | 5.334 ± 4.8807 |
Blood samples were collected at indicated time points for the concentrations of metabolite GSK2531401.
| Nanograms per milliliter | Daprodustat |
|---|---|
| Day 1, Predose, n=45 | 0.000 ± 0.000 |
| Day 1, 0.5 hours, n=43 | 2.927 ± NA |
| Day 1, 1 hour, n=44 | 4.134 ± NA |
| Day 1, 2 hours, n=43 | 11.013 ± 11.9279 |
| Day 1, 3 hours, n=44 | 13.752 ± 14.0238 |
| Day 1, 4 hours, n=43 | 15.497 ± 14.6142 |
| Day 1, 6 hours, n=43 | 18.302 ± 13.9244 |
| Day 1, 8 hours, n=42 | 21.139 ± 13.2221 |
| Day 1, 12 hours, n=40 | 20.174 ± 11.6828 |
| Day 1, 16 hours, n=42 | 20.127 ± 12.1374 |
| Day 1, 24 hours, n=42 | 18.143 ± 11.6065 |
| Day 57, Predose, n=31 | 2.448 ± 2.0199 |
| Day 57, 0.5 hours, n=31 | 4.486 ± 3.9244 |
| Day 57, 1 hour, n=31 | 5.480 ± 5.0425 |
| Day 57, 2 hours, n=30 | 9.015 ± 8.4201 |
| Day 57, 3 hours, n=31 | 14.027 ± 12.7046 |
| Day 57, 4 hours, n=32 | 17.722 ± 14.2802 |
| Day 57, 6 hours, n=30 | 24.285 ± 15.7868 |
| Day 57, 8 hours, n=31 | 25.557 ± 16.2248 |
| Day 57, 12 hours, n=31 | 25.288 ± 15.7597 |
| Day 57, 16 hours, n=31 | 24.881 ± 15.3688 |
| Day 57, 24 hours, n=32 | 21.914 ± 12.9806 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.
| Nanograms per milliliter | Daprodustat |
|---|---|
| Daprodustat, Day 1, n=44 | 218.841 ± 187.869 |
| Daprodustat, Day 57, n=32 | 163.795 ± 330.249 |
| GSK2391220, Day 1, n=44 | 39.506 ± 66.816 |
| GSK2391220, Day 57, n=32 | 44.703 ± 57.029 |
| GSK2487818, Day 1, n=44 | 26.678 ± 79.992 |
| GSK2487818, Day 57, n=32 | 24.846 ± 117.570 |
| GSK2506102, Day 1, n=44 | 9.933 ± 62.188 |
| GSK2506102, Day 57, n=32 | 12.114 ± 46.563 |
| GSK2506104, Day 1, n=44 | 43.169 ± 61.558 |
| GSK2506104, Day 57, n=32 | 51.643 ± 48.087 |
| GSK2531398, Day 1, n=44 | 18.454 ± 67.277 |
| GSK2531398, Day 57, n=32 | 20.362 ± 67.040 |
| GSK2531401, Day 1, n=44 | 18.335 ± 96.906 |
| GSK2531401, Day 57, n=32 | 23.337 ± 75.801 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.
| Hours | Daprodustat |
|---|---|
| Daprodustat, Day 1, n=44 | 2.000 (0.38 to 8.00) |
| Daprodustat, Day 57, n=32 | 2.000 (0.50 to 12.00) |
| GSK2391220, Day 1, n=44 | 4.160 (0.50 to 16.00) |
| GSK2391220, Day 57, n=32 | 4.000 (0.50 to 16.00) |
| GSK2487818, Day 1, n=44 | 3.090 (0.50 to 12.00) |
| GSK2487818, Day 57, n=32 | 4.000 (0.50 to 12.00) |
| GSK2506102, Day 1, n=44 | 6.000 (0.50 to 24.00) |
| GSK2506102, Day 57, n=32 | 6.000 (2.00 to 24.00) |
| GSK2506104, Day 1, n=44 | 6.000 (0.50 to 16.30) |
| GSK2506104, Day 57, n=32 | 5.990 (0.50 to 24.00) |
| GSK2531398, Day 1, n=44 | 4.160 (0.50 to 24.00) |
| GSK2531398, Day 57, n=32 | 4.000 (0.50 to 16.00) |
| GSK2531401, Day 1, n=44 | 8.015 (1.00 to 24.50) |
| GSK2531401, Day 57, n=32 | 8.000 (3.00 to 24.00) |
Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.
| Hours | Daprodustat |
|---|---|
| Daprodustat, Day 1, n=22 | 3.031 ± 40.320 |
| Daprodustat, Day 57, n=10 | 3.635 ± 26.884 |
| GSK2391220, Day 1, n=9 | 6.820 ± 22.096 |
| GSK2391220, Day 57, n=4 | 7.447 ± 7.539 |
| GSK2487818, Day 1, n=20 | 3.388 ± 22.165 |
| GSK2487818, Day 57, n=13 | 3.524 ± 32.634 |
| GSK2506102, Day 1, n=1 | 8.530 ± NA |
| GSK2506102, Day 57, n=32 | NA ± NA |
| GSK2506104, Day 1, n=1 | 6.150 ± NA |
| GSK2506104, Day 57, n=32 | NA ± NA |
| GSK2531398, Day 1, n=11 | 5.582 ± 22.955 |
| GSK2531398, Day 57, n=9 | 6.182 ± 14.307 |
| GSK2531401, Day 1, n=44 | NA ± NA |
| GSK2531401, Day 57, n=32 | NA ± NA |
Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.
| Hour*nanograms per milliliter | Daprodustat |
|---|---|
| Daprodustat, Day 1, n=42 | 767.95 ± 125.63 |
| Daprodustat, Day 57, n=28 | 616.12 ± 168.05 |
| GSK2391220, Day 1, n=42 | 483.12 ± 60.42 |
| GSK2391220, Day 57, n=31 | 516.59 ± 61.78 |
| GSK2487818, Day 1, n=41 | 177.39 ± 66.83 |
| GSK2487818, Day 57, n=28 | 171.09 ± 93.41 |
| GSK2506102, Day 1, n=42 | 166.89 ± 52.93 |
| GSK2506102, Day 57, n=31 | 199.85 ± 44.33 |
| GSK2506104, Day 1, n=42 | 662.23 ± 54.48 |
| GSK2506104, Day 57, n=31 | 756.39 ± 50.29 |
| GSK2531398, Day 1, n=42 | 204.02 ± 59.48 |
| GSK2531398, Day 57, n=31 | 212.04 ± 66.63 |
| GSK2531401, Day 1, n=42 | 334.86 ± 93.49 |
| GSK2531401, Day 57, n=31 | 430.10 ± 73.53 |
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.
| Participants | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Number of Participants With Any Serious Adverse Events (SAEs) | 10 | 5 |
An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Number of participants with treatment emergent common (\>=2% non-SAEs in each arm) non-SAEs has been presented.
| Participants | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Number of Participants With Treatment Emergent Common (>=2%) Non-serious Adverse Events (Non-SAEs) | 10 | 4 |
Number of participants who discontinued the study treatment due to any reason are presented. The reasons for discontinuation included adverse events, protocol specified withdrawal criteria met, physician decision and withdrawal by participant.
| Participants | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Adverse event | 2 | 2 |
| Protocol-specified withdrawal criteria met | 7 | 4 |
| Physician decision | 1 | 1 |
| Withdrawal by participant | 3 | 0 |
Blood samples were collected for the analysis of clinical chemistry parameters including albumin and protein. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| Grams per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Albumin, Baseline (Day1), n=45, 43 | 41.2 ± 3.42 | 40.5 ± 4.21 |
| Albumin, Day 29, n=37, 40 | 39.1 ± 3.58 | 38.3 ± 4.02 |
| Albumin, Day 57, n=31, 35 | 41.4 ± 4.35 | 40.9 ± 4.83 |
| Albumin, Week 10, n=39, 38 | 38.7 ± 3.20 | 38.0 ± 5.19 |
| Protein, Baseline (Day 1), n=45, 43 | 72.3 ± 7.27 | 72.6 ± 8.30 |
| Protein, Day 29, n=37, 40 | 69.4 ± 5.67 | 68.0 ± 7.92 |
| Protein, Day 57, n=31, 35 | 74.0 ± 7.51 | 73.1 ± 8.59 |
| Protein, Week 10, n=39, 38 | 67.5 ± 5.67 | 67.8 ± 7.79 |
Blood samples were collected for the analysis of clinical chemistry parameters including ALP, ALT and AST. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| International units per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| ALP, Baseline (Day1), n=45, 43 | 100.9 ± 51.78 | 100.0 ± 40.47 |
| ALP, Day 29, n=37, 40 | 104.4 ± 49.97 | 95.7 ± 37.28 |
| ALP, Day 57, n=31, 35 | 109.0 ± 48.09 | 101.7 ± 37.81 |
| ALP, Week 10, n=42, 41 | 98.3 ± 54.64 | 98.8 ± 40.03 |
| ALT, Baseline (Day 1), n=45, 43 | 13.8 ± 6.74 | 15.0 ± 6.97 |
| ALT, Day 29, n=37, 40 | 10.4 ± 3.95 | 12.0 ± 5.80 |
| ALT, Day 57, n=31, 35 | 11.0 ± 5.75 | 12.9 ± 5.07 |
| ALT, Week 10, n=42, 41 | 10.6 ± 4.71 | 12.3 ± 7.01 |
| AST, Baseline (Day 1), n=45, 43 | 16.8 ± 6.63 | 17.0 ± 6.07 |
| AST, Day 29, n=37, 40 | 13.2 ± 4.76 | 13.7 ± 5.68 |
| AST, Day 57, n=31, 35 | 14.9 ± 5.12 | 15.2 ± 4.23 |
| AST, Week 10, n=42, 41 | 14.0 ± 5.18 | 15.2 ± 10.86 |
Blood samples were collected for the analysis of clinical chemistry parameters including direct bilirubin, total bilirubin and Indrt bilirubin. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| Micromoles per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Direct bilirubin,Baseline(Day1),n=45,43 | 2.0 ± 1.24 | 1.8 ± 1.17 |
| Direct bilirubin, Day 29, n=37, 39 | 1.9 ± 1.05 | 1.7 ± 1.23 |
| Direct bilirubin, Day 57, n=31, 35 | 1.9 ± 1.21 | 1.8 ± 1.35 |
| Direct bilirubin, Week 10, n=39, 38 | 1.8 ± 0.89 | 1.7 ± 1.09 |
| Total bilirubin, Baseline (Day 1),n=45,43 | 8.6 ± 3.07 | 7.7 ± 3.25 |
| Total bilirubin, Day 29, n=37, 39 | 7.1 ± 2.19 | 7.2 ± 1.93 |
| Total bilirubin, Day 57, n=31, 35 | 9.0 ± 3.86 | 8.6 ± 2.69 |
| Total bilirubin, Week 10, n=42, 41 | 7.7 ± 2.29 | 7.0 ± 2.20 |
| Indrt bilirubin, Baseline (Day 1), n=45,43 | 6.6 ± 2.28 | 6.0 ± 2.74 |
| Indrt bilirubin, Day 29, n=37, 39 | 5.2 ± 1.79 | 5.4 ± 1.89 |
| Indrt bilirubin, Day 57, n=31, 35 | 7.0 ± 3.30 | 6.9 ± 2.02 |
| Indrt bilirubin, Week 10, n=39, 38 | 5.9 ± 2.08 | 5.3 ± 1.83 |
Blood samples were collected for the analysis of clinical chemistry parameters including CCA, glucose, potassium, phosphate and sodium. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| Millimoles per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| CCA, Baseline (Day 1),n=45,43 | 2.254 ± 0.1147 | 2.266 ± 0.1341 |
| CCA, Day 29, n=37, 40 | 2.242 ± 0.1692 | 2.242 ± 0.1479 |
| CCA, Day 57, n=31, 35 | 2.240 ± 0.1389 | 2.265 ± 0.1086 |
| CCA, Week 10, n=39, 38 | 2.227 ± 0.1599 | 2.232 ± 0.1644 |
| Glucose, Baseline (Day 1), n=45,43 | 7.40 ± 2.794 | 7.67 ± 3.504 |
| Glucose, Day 29, n=37, 40 | 8.28 ± 4.234 | 7.35 ± 2.362 |
| Glucose, Day 57, n=31, 35 | 7.27 ± 2.419 | 7.01 ± 2.690 |
| Glucose, Week 10, n=39, 38 | 7.98 ± 3.020 | 7.36 ± 2.948 |
| Potassium, Baseline (Day 1), n=45,43 | 3.99 ± 0.509 | 4.06 ± 0.788 |
| Potassium, Day 29, n=37, 40 | 4.39 ± 0.769 | 4.60 ± 0.765 |
| Potassium, Day 57, n=31, 35 | 3.81 ± 0.414 | 4.01 ± 0.663 |
| Potassium, Week 10, n=39, 38 | 4.66 ± 0.639 | 4.65 ± 0.693 |
| Phosphate, Baseline (Day 1), n=45,43 | 1.129 ± 0.4792 | 1.242 ± 0.5758 |
| Phosphate, Day 29, n=37, 40 | 1.455 ± 0.5207 | 1.761 ± 0.6297 |
| Phosphate, Day 57, n=31, 35 | 0.953 ± 0.2523 | 1.274 ± 0.6260 |
| Phosphate, Week 10, n=39, 38 | 1.629 ± 0.560 | 1.849 ± 0.5431 |
| Sodium, Baseline (Day 1), n=45,43 | 137.9 ± 2.64 | 138.0 ± 2.58 |
| Sodium, Day 29, n=37, 40 | 137.8 ± 2.41 | 138.4 ± 2.84 |
| Sodium, Day 57, n=31, 35 | 137.7 ± 2.22 | 138.6 ± 2.74 |
| Sodium, Week 10, n=39, 38 | 137.9 ± 2.28 | 138.6 ± 2.77 |
Blood samples were collected for the analysis of clinical chemistry parameters including albumin and protein. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Grams per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Albumin, Day 29, n=37, 40 | -2.2 ± 3.67 | -2.4 ± 3.42 |
| Albumin, Day 57, n=31, 35 | 0.4 ± 3.60 | 0.5 ± 3.16 |
| Albumin, Week 10, n=39, 38 | -2.9 ± 3.10 | -2.4 ± 3.93 |
| Protein, Day 29, n=37, 40 | -3.7 ± 6.41 | -4.7 ± 6.03 |
| Protein, Day 57, n=31, 35 | 1.2 ± 6.44 | 0.7 ± 5.64 |
| Protein, Week 10, n=39, 38 | -5.2 ± 5.90 | -4.9 ± 5.69 |
Blood samples were collected for the analysis of clinical chemistry parameters including ALP, ALT and AST. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| International units per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| ALP, Day 29, n=37, 40 | -3.4 ± 19.56 | -5.3 ± 27.57 |
| ALP, Day 57, n=31, 35 | 0.5 ± 23.21 | 3.4 ± 17.93 |
| ALP, Week 10, n=42, 41 | -4.5 ± 29.46 | -1.9 ± 25.70 |
| ALT, Day 29, n=37, 40 | -3.2 ± 5.74 | -2.6 ± 6.36 |
| ALT, Day 57, n=31, 35 | -3.1 ± 7.93 | -1.9 ± 5.93 |
| ALT, Week 10, n=42, 41 | -3.3 ± 7.31 | -2.8 ± 4.96 |
| AST, Day 29, n=37, 40 | -3.2 ± 4.90 | -3.0 ± 5.38 |
| AST, Day 57, n=31, 35 | -2.1 ± 6.10 | -1.9 ± 4.60 |
| AST, Week 10, n=42, 41 | -3.3 ± 6.10 | -2.0 ± 9.11 |
Blood samples were collected for the analysis of clinical chemistry parameters including direct bilirubin, total bilirubin and indrt. bilirubin. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Micromoles per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Direct bilirubin, Day 29, n=37, 39 | -0.1 ± 1.05 | -0.1 ± 1.69 |
| Direct bilirubin, Day 57, n=31, 35 | -0.1 ± 1.21 | -0.1 ± 1.37 |
| Direct bilirubin, Week 10, n=39, 38 | -0.3 ± 1.14 | -0.1 ± 1.18 |
| Total bilirubin, Day 29, n=37, 39 | -1.5 ± 2.19 | -0.8 ± 3.10 |
| Total bilirubin, Day 57, n=31, 35 | 0.6 ± 2.74 | 0.7 ± 2.70 |
| Total bilirubin, Week 10, n=42, 41 | -1.0 ± 2.62 | -0.8 ± 2.23 |
| Indrt bilirubin, Day 29, n=37, 39 | -1.4 ± 2.06 | -0.7 ± 2.92 |
| Indrt bilirubin, Day 57, n=31, 35 | 0.6 ± 2.80 | 0.9 ± 2.80 |
| Indrt bilirubin, Week 10, n=39, 38 | -0.8 ± 2.28 | -0.5 ± 2.01 |
Blood samples were collected for the analysis of clinical chemistry parameters including CCA, glucose, potassium, phosphate and sodium. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Millimoles per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| CCA, Day 29, n=37, 40 | 0.000 ± 0.1384 | -0.021 ± 0.1699 |
| CCA, Day 57, n=31, 35 | 0.004 ± 0.1344 | -0.000 ± 0.1450 |
| CCA, Week 10, n=39, 38 | -0.010 ± 0.1693 | -0.033 ± 0.1284 |
| Glucose, Day 29, n=37, 40 | 0.75 ± 4.331 | -0.48 ± 3.771 |
| Glucose, Day 57, n=31, 35 | -0.45 ± 2.403 | -0.83 ± 2.684 |
| Glucose, Week 10, n=39, 38 | 0.62 ± 3.001 | -0.18 ± 2.916 |
| Potassium, Day 29, n=37, 40 | 0.45 ± 0.790 | 0.53 ± 0.863 |
| Potassium, Day 57, n=31, 35 | -0.14 ± 0.512 | -0.04 ± 0.696 |
| Potassium, Week 10, n=39, 38 | 0.67 ± 0.694 | 0.58 ± 0.746 |
| Phosphate, Day 29, n=37, 40 | 0.389 ± 0.6876 | 0.513 ± 0.7270 |
| Phosphate, Day 57, n=31, 35 | -0.123 ± 0.4624 | 0.004 ± 0.5274 |
| Phosphate, Week 10, n=39, 38 | 0.505 ± 0.7016 | 0.599 ± 0.6723 |
| Sodium, Day 29, n=37, 40 | -0.1 ± 3.25 | 0.3 ± 3.22 |
| Sodium, Day 57, n=31, 35 | 0.2 ± 2.47 | 0.6 ± 2.71 |
| Sodium, Week 10, n=39, 38 | -0.2 ± 2.41 | 0.5 ± 2.53 |
Blood samples were collected for the analysis of hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| 10^9 cells per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Basophils, Baseline (Day 1), n=45, 41 | 0.050 ± 0.0295 | 0.044 ± 0.0255 |
| Basophils, Day 29, n=37, 39 | 0.045 ± 0.0301 | 0.054 ± 0.0312 |
| Basophils, Day 57, n=30, 35 | 0.049 ± 0.0349 | 0.045 ± 0.0243 |
| Basophils, Week 10, n=39, 38 | 0.044 ± 0.0261 | 0.054 ± 0.0284 |
| Eosinophils, Baseline (Day 1), n=45, 41 | 0.196 ± 0.1520 | 0.229 ± 0.2324 |
| Eosinophils, Day 29, n=37, 39 | 0.238 ± 0.2301 | 0.191 ± 0.1551 |
| Eosinophils, Day 57, n=30, 35 | 0.218 ± 0.1811 | 0.160 ± 0.1505 |
| Eosinophils, Week 10, n=39, 38 | 0.231 ± 0.1918 | 0.184 ± 0.1167 |
| Lymphocytes, Baseline (Day 1), n=45, 41 | 1.257 ± 0.3926 | 1.307 ± 0.6305 |
| Lymphocytes, Day 29, n=37, 39 | 1.385 ± 0.5446 | 1.436 ± 0.5798 |
| Lymphocytes, Day 57, n=30, 35 | 1.209 ± 0.5062 | 1.225 ± 0.6698 |
| Lymphocytes, Week 10, n=39, 38 | 1.367 ± 0.5559 | 1.408 ± 0.6788 |
| Monocytes, Baseline (Day 1), n=45, 41 | 0.398 ± 0.1471 | 0.408 ± 0.1752 |
| Monocytes, Day 29, n=37, 39 | 0.442 ± 0.1664 | 0.460 ± 0.1812 |
| Monocytes, Day 57, n=30, 35 | 0.432 ± 0.1621 | 0.448 ± 0.2204 |
| Monocytes, Week 10, n=39, 38 | 0.469 ± 0.1640 | 0.443 ± 0.1773 |
| Neutrophils, Baseline (Day 1), n=45, 41 | 4.091 ± 1.6571 | 4.053 ± 1.4574 |
| Neutrophils, Day 29, n=37, 39 | 4.319 ± 1.3509 | 4.242 ± 1.5623 |
| Neutrophils, Day 57, n=30, 35 | 4.381 ± 1.9926 | 4.377 ± 1.6450 |
| Neutrophils, Week 10, n=39, 38 | 4.250 ± 1.8123 | 4.369 ± 1.7463 |
| Platelets, Baseline (Day 1), n=45, 42 | 188.5 ± 67.64 | 193.8 ± 70.03 |
| Platelets, Day 29, n=37, 38 | 195.2 ± 66.55 | 222.1 ± 82.78 |
| Platelets, Day 57, n=30, 34 | 207.8 ± 95.04 | 213.5 ± 67.33 |
| Platelets, Week 10, n=39, 38 | 209.3 ± 75.61 | 229.5 ± 78.29 |
| Leukocytes, Baseline (Day 1), n=45, 41 | 6.00 ± 1.923 | 6.04 ± 1.897 |
| Leukocytes, Day 29, n=37, 39 | 6.43 ± 1.678 | 6.38 ± 2.145 |
| Leukocytes, Day 57, n=30, 35 | 6.29 ± 2.363 | 6.25 ± 2.044 |
| Leukocytes, Week 10, n=39, 38 | 6.35 ± 2.178 | 6.45 ± 2.297 |
Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| Proportion of red blood cells in blood | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Baseline (Day 1), n=45, 42 | 0.3133 ± 0.03111 | 0.3242 ± 0.03046 |
| Day 29, n=37, 39 | 0.3066 ± 0.03195 | 0.3113 ± 0.03307 |
| Day 57, n=31, 35 | 0.3196 ± 0.03046 | 0.3397 ± 0.02476 |
| Week 10, n=39, 38 | 0.3050 ± 0.03743 | 0.3209 ± 0.03375 |
Blood samples were collected for the analysis of hematology parameters: erythrocytes and reticulocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| 10^12 cells per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Erythrocytes, Baseline (Day 1), n=45, 42 | 3.31 ± 0.378 | 3.45 ± 0.388 |
| Erythrocytes, Day 29, n=37, 39 | 3.20 ± 0.361 | 3.27 ± 0.499 |
| Erythrocytes, Day 57, n=31, 35 | 3.34 ± 0.393 | 3.53 ± 0.357 |
| Erythrocytes, Week 10, n=39, 38 | 3.13 ± 0.388 | 3.38 ± 0.470 |
| Reticulocytes, Baseline (Day 1), n=45, 42 | 0.0302 ± 0.01536 | 0.0401 ± 0.02614 |
| Reticulocytes, Day 29, n=37, 39 | 0.0486 ± 0.01676 | 0.0733 ± 0.03493 |
| Reticulocytes, Day 57, n=31, 35 | 0.0489 ± 0.01681 | 0.0627 ± 0.03344 |
| Reticulocytes, Week 10, n=39, 38 | 0.0613 ± 0.03932 | 0.0566 ± 0.03060 |
Blood samples were collected for the analysis of hematology parameters: hemoglobin and ery.MCHC. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| Grams per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Hemoglobin, Baseline (Day 1), n=45, 42 | 102.2 ± 9.15 | 104.5 ± 8.83 |
| Hemoglobin, Day 29, n=37, 39 | 100.2 ± 10.01 | 99.7 ± 9.63 |
| Hemoglobin, Day 57, n=31, 35 | 105.2 ± 9.61 | 107.9 ± 6.01 |
| Hemoglobin, Week 10, n=39, 38 | 99.6 ± 12.44 | 102.9 ± 10.54 |
| ery.MCHC, Baseline (Day 1), n=45, 42 | 326.7 ± 9.01 | 322.6 ± 8.41 |
| ery.MCHC, Day 29, n=37, 39 | 327.1 ± 6.57 | 320.8 ± 11.50 |
| ery.MCHC, Day 57, n=31, 35 | 329.0 ± 6.62 | 318.3 ± 15.46 |
| ery.MCHC, Week 10, n=39, 38 | 326.7 ± 9.26 | 320.6 ± 9.17 |
Blood samples were collected for the analysis of hematology parameter: ery.MCH and CHr. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| Picograms | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| ery. MCH, Baseline (Day 1), n=45, 42 | 31.03 ± 2.295 | 30.57 ± 2.880 |
| ery. MCH, Day 29, n=37, 39 | 31.56 ± 2.302 | 30.83 ± 3.051 |
| ery. MCH, Day 57, n=31, 35 | 31.75 ± 2.312 | 30.88 ± 3.140 |
| ery. MCH, Week 10, n=39, 38 | 31.96 ± 2.246 | 30.66 ± 2.823 |
| CHr, Baseline (Day 1), n=45, 43 | 30.70 ± 1.730 | 29.97 ± 2.088 |
| CHr, Day 29, n=36, 40 | 30.55 ± 1.799 | 30.19 ± 2.242 |
| CHr, Day 57, n=32, 36 | 30.71 ± 1.852 | 29.85 ± 2.462 |
| CHr, Week 10, n=39, 39 | 30.55 ± 2.116 | 29.76 ± 2.079 |
Blood samples were collected for the analysis of hematology parameter: ery.MCV. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| Femtoliters | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Baseline (Day 1), n=45, 42 | 95.0 ± 6.33 | 94.8 ± 8.37 |
| Day 29, n=37, 39 | 96.5 ± 6.92 | 96.2 ± 8.76 |
| Day 57, n=31, 35 | 96.5 ± 7.18 | 97.1 ± 9.04 |
| Week 10, n=39, 38 | 97.9 ± 6.61 | 95.7 ± 8.37 |
Blood samples were collected for the analysis of hematology parameter: erythrocyte distribution width. Baseline value (Day1) is the latest non-missing pre-dose assessment.
| Percentage of width | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Baseline (Day 1), n=45, 42 | 16.06 ± 1.618 | 15.71 ± 1.917 |
| Day 29, n=37, 39 | 16.52 ± 1.802 | 16.75 ± 2.230 |
| Day 57, n=31, 35 | 16.11 ± 1.476 | 16.67 ± 2.034 |
| Week 10, n=39, 38 | 16.42 ± 2.036 | 16.45 ± 1.696 |
Blood samples were collected for the analysis of hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| 10^9 cells per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Basophils, Day 29, n=37, 37 | -0.007 ± 0.0317 | 0.010 ± 0.0329 |
| Basophils, Day 57, n=30, 33 | -0.002 ± 0.0331 | 0.004 ± 0.0335 |
| Basophils, Week 10, n=39, 36 | -0.004 ± 0.0349 | 0.009 ± 0.0323 |
| Eosinophils, Day 29, n=37, 37 | 0.040 ± 0.1717 | -0.039 ± 0.1728 |
| Eosinophils, Day 57, n=30, 33 | 0.016 ± 0.1513 | -0.038 ± 0.1202 |
| Eosinophils, Week 10, n=39, 36 | 0.042 ± 0.1435 | -0.036 ± 0.1702 |
| Lymphocytes, Day 29, n=37, 37 | 0.095 ± 0.3613 | 0.102 ± 0.4154 |
| Lymphocytes, Day 57, n=30, 33 | -0.090 ± 0.3036 | -0.099 ± 0.3277 |
| Lymphocytes, Week 10, n=39, 36 | 0.103 ± 0.3893 | 0.078 ± 0.4660 |
| Monocytes, Day 29, n=37, 37 | 0.033 ± 0.1600 | 0.035 ± 0.1266 |
| Monocytes, Day 57, n=30, 33 | 0.024 ± 0.1621 | 0.025 ± 0.1543 |
| Monocytes, Week 10, n=39, 36 | 0.070 ± 0.1398 | 0.053 ± 0.1248 |
| Neutrophils, Day 29, n=37, 37 | 0.071 ± 1.1706 | 0.061 ± 1.3382 |
| Neutrophils, Day 57, n=30, 33 | 0.081 ± 1.2291 | 0.325 ± 1.1549 |
| Neutrophils, Week 10, n=39, 36 | 0.218 ± 1.3096 | 0.181 ± 0.9586 |
| Platelets, Day 29, n=37, 37 | 0.6 ± 31.12 | 22.7 ± 52.46 |
| Platelets, Day 57, n=30, 33 | 13.9 ± 47.04 | 16.4 ± 39.51 |
| Platelets, Week 10, n=39, 37 | 20.6 ± 36.08 | 26.3 ± 41.87 |
| Leukocytes, Day 29, n=37, 37 | 0.23 ± 1.296 | 0.17 ± 1.555 |
| Leukocytes, Day 57, n=30, 33 | 0.02 ± 1.456 | 0.21 ± 1.231 |
| Leukocytes, Week 10, n=39, 36 | 0.42 ± 1.442 | 0.28 ± 1.220 |
Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Proportion of red blood cells in blood | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Day 29, n=37, 38 | -0.0131 ± 0.03062 | -0.0136 ± 0.02614 |
| Day 57, n=31, 34 | -0.0016 ± 0.03717 | 0.0131 ± 0.03609 |
| Week 10, n=39, 37 | -0.0096 ± 0.04571 | -0.0054 ± 0.04944 |
Blood samples were collected for the analysis of hematology parameters: erythrocytes and reticulocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| 10^12 cells per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Erythrocytes, Day 29, n=37, 38 | -0.17 ± 0.331 | -0.20 ± 0.273 |
| Erythrocytes, Day 57, n=31, 34 | -0.06 ± 0.410 | 0.04 ± 0.307 |
| Erythrocytes, Week 10, n=39, 37 | -0.18 ± 0.488 | -0.11 ± 0.497 |
| Reticulocytes, Day 29, n=37, 38 | 0.0156 ± 0.01432 | 0.0315 ± 0.03821 |
| Reticulocytes, Day 57, n=31, 34 | 0.0169 ± 0.01709 | 0.0204 ± 0.02182 |
| Reticulocytes, Week 10, n=39, 37 | 0.0314 ± 0.04385 | 0.0159 ± 0.02321 |
Blood samples were collected for the analysis of hematology parameters: hemoglobin and ery.MCHC. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Grams per liter | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Hemoglobin, Day 29, n=37, 38 | -4.1 ± 9.35 | -5.1 ± 8.21 |
| Hemoglobin, Day 57, n=31, 34 | 0.5 ± 10.60 | 2.5 ± 8.54 |
| Hemoglobin, Week 10, n=39, 37 | -3.2 ± 14.35 | -1.8 ± 14.46 |
| ery.MCHC, Day 29, n=37, 38 | 0.3 ± 8.41 | -2.0 ± 10.38 |
| ery.MCHC, Day 57, n=31, 34 | 2.3 ± 8.83 | -4.4 ± 14.46 |
| ery.MCHC, Week 10, n=39, 37 | -0.6 ± 9.37 | -0.8 ± 11.20 |
Blood samples were collected for the analysis of hematology parameter: ery.MCH and CHr. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Picograms | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| ery. MCH, Day 29, n=37, 38 | 0.39 ± 0.676 | 0.40 ± 0.672 |
| ery. MCH, Day 57, n=31, 34 | 0.70 ± 1.161 | 0.49 ± 0.871 |
| ery. MCH, Week 10, n=39, 37 | 0.78 ± 1.249 | 0.38 ± 1.000 |
| CHr, Day 29, n=36, 40 | -0.23 ± 0.937 | 0.20 ± 1.060 |
| CHr, Day 57, n=32, 36 | -0.12 ± 1.067 | -0.09 ± 1.617 |
| CHr, Week 10, n=39, 39 | -0.29 ± 1.696 | -0.03 ± 1.478 |
Blood samples were collected for the analysis of hematology parameter: ery.MCV. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Femtoliters | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Day 29, n=37, 38 | 1.2 ± 2.47 | 1.8 ± 3.32 |
| Day 57, n=31, 34 | 1.5 ± 3.50 | 2.9 ± 3.54 |
| Week 10, n=39, 37 | 2.7 ± 4.80 | 1.4 ± 3.62 |
Blood samples were collected for the analysis of hematology parameter: erythrocyte distribution width. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Percentage of width | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Day 29, n=37, 38 | 0.38 ± 1.197 | 1.09 ± 1.435 |
| Day 57, n=31, 34 | 0.12 ± 1.262 | 0.85 ± 1.609 |
| Week 10, n=39, 37 | 0.35 ± 1.998 | 0.59 ± 1.650 |
Full 12-lead ECGs were obtained in supine position using an ECG machine to measure mean heart rate. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.
| Beats per minute | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Baseline (Day 1-predose), n=45, 43 | 72.2 ± 9.52 | 73.6 ± 9.03 |
| Day 1: 24 hours, n=40, 38 | 71.6 ± 9.38 | 74.8 ± 9.42 |
| Day 57: predose, n=32, 36 | 71.2 ± 8.58 | 72.7 ± 9.47 |
| Day 57: 24 hours, n=32, 36 | 71.2 ± 8.22 | 75.1 ± 9.12 |
| Week 10, n=39, 40 | 72.3 ± 10.03 | 74.3 ± 9.53 |
Full 12-lead ECGs were obtained in supine position using an ECG machine to measure ECG parameters: PR interval, QRS duration, QTc interval and QTcB. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.
| Milliseconds | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| PR interval, Baseline (Day 1-predose), n=45, 43 | 156.5 ± 30.81 | 160.5 ± 30.79 |
| PR interval, Day 1: 24 hours, n=39, 38 | 158.1 ± 30.26 | 163.3 ± 34.38 |
| PR interval, Day 57: predose, n=32, 35 | 155.8 ± 27.69 | 152.1 ± 26.90 |
| PR interval, Day 57: 24 hours, n=32, 36 | 156.4 ± 29.83 | 160.3 ± 32.98 |
| PR interval, Week 10, n=39, 40 | 162.5 ± 29.19 | 159.9 ± 31.16 |
| QRS duration, Baseline (Day 1-predose), n=45, 43 | 106.2 ± 18.40 | 107.4 ± 16.22 |
| QRS duration, Day 1: 24 hours, n=40, 38 | 106.0 ± 17.31 | 107.4 ± 17.85 |
| QRS duration, Day 57: predose, n=32, 36 | 106.7 ± 14.46 | 112.4 ± 21.89 |
| QRS duration, Day 57: 24 hours, n=32, 36 | 106.4 ± 15.05 | 111.0 ± 20.75 |
| QRS duration, Week 10, n=39, 40 | 108.5 ± 15.56 | 109.1 ± 20.69 |
| QTc interval, Baseline (Day 1-predose), n=9, 17 | 440.6 ± 22.41 | 429.4 ± 27.49 |
| QTc interval, Day 1: 24 hours, n=7, 11 | 446.1 ± 18.94 | 424.7 ± 27.73 |
| QTc interval, Day 57: predose, n=5, 8 | 452.8 ± 13.92 | 436.1 ± 21.72 |
| QTc interval, Day 57: 24 hours, n=5, 8 | 430.6 ± 14.84 | 431.8 ± 31.98 |
| QTc interval, Week 10, n=6, 10 | 438.8 ± 13.01 | 428.3 ± 31.87 |
| QTcB, Baseline (Day 1-predose), n=45, 43 | 448.0 ± 40.17 | 445.6 ± 31.00 |
| QTcB, Day 1: 24 hours, n=40, 38 | 438.9 ± 35.02 | 439.3 ± 25.64 |
| QTcB, Day 57: predose, n=32, 36 | 442.3 ± 38.12 | 449.1 ± 32.58 |
| QTcB, Day 57: 24 hours, n=32, 36 | 437.4 ± 33.58 | 442.0 ± 37.61 |
| QTcB, Week 10, n=39, 39 | 442.0 ± 37.28 | 441.6 ± 28.11 |
Full 12-lead ECGs were obtained in supine position using an ECG machine to measure mean heart rate. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Beats per minute | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Day 1: 24 hours, n=40, 38 | -0.6 ± 6.85 | 0.8 ± 5.61 |
| Day 57: predose, n=32, 36 | -1.6 ± 7.25 | 0.1 ± 8.22 |
| Day 57: 24 hours, n=32, 36 | -1.7 ± 6.58 | 2.5 ± 8.21 |
| Week 10, n=39, 40 | -0.1 ± 9.01 | 0.4 ± 8.86 |
Full 12-lead ECGs were obtained in supine position using an ECG machine to measure ECG parameters: PR interval, QRS duration, QTc interval and QTcB. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Milliseconds | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| PR interval, Day 1: 24 hours, n=39, 38 | 3.0 ± 11.02 | 1.9 ± 11.16 |
| PR interval, Day 57: predose, n=32, 35 | 0.2 ± 17.58 | -3.9 ± 11.34 |
| PR interval, Day 57: 24 hours, n=32, 36 | 0.8 ± 15.89 | 1.8 ± 13.03 |
| PR interval, Week 10, n=39, 40 | 4.9 ± 15.21 | 1.2 ± 17.11 |
| QRS duration, Day 1: 24 hours, n=40, 38 | -0.5 ± 7.60 | 0.0 ± 4.73 |
| QRS duration, Day 57: predose, n=32, 36 | 0.3 ± 9.53 | 2.8 ± 15.01 |
| QRS duration, Day 57: 24 hours, n=32, 36 | 0.0 ± 11.13 | 1.4 ± 13.22 |
| QRS duration, Week 10, n=39, 40 | 0.8 ± 12.62 | 0.7 ± 18.38 |
| QTc interval, Day 1: 24 hours, n=7, 11 | 2.1 ± 14.59 | -9.4 ± 14.87 |
| QTc interval, Day 57: predose, n=4, 8 | -6.3 ± 20.14 | 1.0 ± 5.71 |
| QTc interval, Day 57: 24 hours, n=4, 8 | -29.0 ± 31.89 | -3.4 ± 14.79 |
| QTc interval, Week 10, n=6, 9 | -6.7 ± 25.15 | -10.3 ± 11.74 |
| QTcB, Day 1: 24 hours, n=40, 38 | -7.0 ± 24.13 | -3.1 ± 12.31 |
| QTcB, Day 57: predose, n=32, 36 | -7.0 ± 30.14 | 4.9 ± 12.36 |
| QTcB, Day 57: 24 hours, n=32, 36 | -12.0 ± 29.93 | -2.2 ± 23.15 |
| QTcB, Week 10, n=39, 39 | -7.2 ± 35.84 | -3.0 ± 15.34 |
Vital signs including SBP and DBP were measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.
| Millimeters of mercury | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| SBP, Baseline (Day1, predose), n=45, 43 | 135.87 ± 20.813 | 137.00 ± 16.547 |
| SBP, Day 1: 3 hours, n=44, 43 | 140.64 ± 18.183 | 144.05 ± 22.184 |
| SBP, Day1: 12 hours, n=44, 43 | 142.05 ± 23.150 | 143.56 ± 20.566 |
| SBP, Day 1: 24 hours, n=41, 40 | 140.24 ± 20.960 | 142.05 ± 14.822 |
| SBP, Day 29: pre-dialysis, n=38, 40 | 143.05 ± 20.351 | 148.10 ± 20.445 |
| SBP, Day 29: post dialysis, n=38, 40 | 130.97 ± 20.608 | 141.93 ± 19.038 |
| SBP, Day 57: pre-dialysis, n=32, 36 | 142.75 ± 22.599 | 151.53 ± 19.893 |
| SBP, Day 57: post dialysis, n=32, 36 | 135.66 ± 18.314 | 141.64 ± 20.304 |
| SBP, Day 57: 3 hours, n=32, 36 | 140.94 ± 22.623 | 148.06 ± 20.316 |
| SBP, Day 57: 12 hours, n=32, 36 | 130.47 ± 22.492 | 145.47 ± 18.599 |
| SBP, Day 57: 24 hours, n=32, 36 | 143.78 ± 17.783 | 144.83 ± 15.497 |
| SBP, Week 10: pre-dialysis, n=42, 42 | 142.71 ± 20.123 | 147.12 ± 18.285 |
| SBP, Week 10: post dialysis, n=41, 42 | 138.73 ± 19.584 | 136.74 ± 22.105 |
| DBP, Baseline (Day1, predose), n=45, 43 | 70.00 ± 10.967 | 72.05 ± 11.307 |
| DBP, Day 1: 3 hours, n=44, 43 | 74.91 ± 12.676 | 75.53 ± 11.701 |
| DBP, Day1: 12 hours, n=44, 43 | 77.11 ± 13.784 | 77.19 ± 12.557 |
| DBP, Day 1: 24 hours, n=41, 40 | 74.22 ± 11.010 | 76.18 ± 10.318 |
| DBP, Day 29: pre-dialysis, n=38, 40 | 71.92 ± 10.794 | 77.95 ± 12.850 |
| DBP, Day 29: post dialysis, n=38, 40 | 69.47 ± 11.272 | 73.30 ± 10.823 |
| DBP, Day 57: pre-dialysis, n=32, 36 | 72.69 ± 9.855 | 76.69 ± 12.578 |
| DBP, Day 57: post dialysis, n=32, 36 | 71.47 ± 10.586 | 72.56 ± 10.383 |
| DBP, Day 57: 3 hours, n=32, 36 | 72.44 ± 13.023 | 75.72 ± 11.732 |
| DBP, Day 57: 12 hours, n=32, 36 | 67.38 ± 10.536 | 75.94 ± 10.376 |
| DBP, Day 57: 24 hours, n=32, 36 | 76.44 ± 12.425 | 74.81 ± 8.756 |
| DBP, Week 10: pre-dialysis, n=42, 42 | 73.86 ± 12.479 | 75.83 ± 10.087 |
| DBP, Week 10: post dialysis, n=41, 42 | 71.05 ± 12.008 | 69.52 ± 10.341 |
Temperature was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.
| Degrees celsius | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Baseline (Day1, predose), n=45, 43 | 36.456 ± 0.3708 | 36.442 ± 0.3692 |
| Day 1: 3 hours, n=44, 43 | 36.427 ± 0.3480 | 36.374 ± 0.3102 |
| Day1: 12 hours, n=44, 43 | 36.470 ± 0.4032 | 36.507 ± 0.4125 |
| Day 1: 24 hours, n=41, 40 | 36.459 ± 0.3598 | 36.380 ± 0.3539 |
| Day 29: pre-dialysis, n=38, 40 | 36.389 ± 0.3547 | 36.418 ± 0.3169 |
| Day 29: post dialysis, n=38, 40 | 36.316 ± 0.3576 | 36.380 ± 0.3040 |
| Day 57: pre-dialysis, n=32, 36 | 36.419 ± 0.3685 | 36.403 ± 0.3410 |
| Day 57: post dialysis, n=32, 36 | 36.384 ± 0.3028 | 36.378 ± 0.2977 |
| Day 57: 3 hours, n=32, 36 | 36.422 ± 0.3066 | 36.497 ± 0.4018 |
| Day 57: 12 hours, n=32, 36 | 36.525 ± 0.4363 | 36.414 ± 0.3474 |
| Day 57: 24 hours, n=32, 36 | 36.447 ± 0.3360 | 36.506 ± 0.3014 |
| Week 10: pre-dialysis, n=42, 42 | 36.414 ± 0.3375 | 36.383 ± 0.2469 |
| Week 10: post dialysis, n=41, 42 | 36.461 ± 0.3767 | 36.450 ± 0.2625 |
Pulse rate was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.
| Beats per minute | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Baseline (Day1, predose), n=45, 43 | 72.09 ± 9.860 | 76.19 ± 11.450 |
| Day 1: 3 hours, n=44, 43 | 72.48 ± 9.931 | 76.21 ± 10.432 |
| Day1: 12 hours, n=44, 43 | 71.95 ± 9.101 | 72.65 ± 9.564 |
| Day 1: 24 hours, n=41, 40 | 73.37 ± 10.495 | 76.43 ± 8.388 |
| Day 29: pre-dialysis, n=38, 40 | 72.92 ± 11.751 | 76.05 ± 8.688 |
| Day 29: post dialysis, n=38, 40 | 74.00 ± 10.051 | 76.18 ± 11.437 |
| Day 57: pre-dialysis, n=32, 36 | 74.59 ± 12.793 | 77.17 ± 10.997 |
| Day 57: post dialysis, n=32, 36 | 72.63 ± 10.354 | 75.75 ± 9.927 |
| Day 57: 3 hours, n=32, 36 | 70.91 ± 11.360 | 75.25 ± 9.755 |
| Day 57: 12 hours, n=32, 36 | 70.50 ± 11.259 | 75.11 ± 9.858 |
| Day 57: 24 hours, n=32, 36 | 71.16 ± 10.097 | 75.36 ± 7.650 |
| Week 10: pre-dialysis, n=42, 42 | 73.07 ± 10.744 | 75.81 ± 9.823 |
| Week 10: post dialysis, n=41, 42 | 71.76 ± 10.138 | 74.55 ± 11.096 |
Vital signs including SBP and DBP were measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Millimeters of mercury | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| SBP, Day 1: 3 hours, n=44, 43 | 5.34 ± 20.307 | 7.05 ± 18.639 |
| SBP, Day1: 12 hours, n=44, 43 | 6.75 ± 25.642 | 6.56 ± 17.633 |
| SBP, Day 1: 24 hours, n=41, 40 | 3.90 ± 21.846 | 6.23 ± 18.150 |
| SBP, Day 29: pre-dialysis, n=38, 40 | 8.24 ± 27.069 | 12.00 ± 25.314 |
| SBP, Day 29: post dialysis, n=38, 40 | -3.84 ± 20.676 | 5.83 ± 21.882 |
| SBP, Day 57: pre-dialysis, n=32, 36 | 6.63 ± 25.125 | 16.03 ± 20.492 |
| SBP, Day 57: post dialysis, n=32, 36 | -0.47 ± 22.747 | 6.14 ± 20.699 |
| SBP, Day 57: 3 hours, n=32, 36 | 4.81 ± 22.938 | 12.56 ± 20.832 |
| SBP, Day 57: 12 hours, n=32, 36 | -5.66 ± 25.575 | 9.97 ± 20.520 |
| SBP, Day 57: 24 hours, n=32, 36 | 7.66 ± 21.919 | 9.33 ± 22.080 |
| SBP, Week 10: pre-dialysis, n=42, 42 | 7.36 ± 21.412 | 10.48 ± 19.261 |
| SBP, Week 10: post dialysis, n=41, 42 | 2.73 ± 19.005 | 0.10 ± 23.472 |
| DBP, Day 1: 3 hours, n=44, 43 | 5.07 ± 12.617 | 3.49 ± 13.170 |
| DBP, Day1: 12 hours, n=44, 43 | 7.27 ± 13.588 | 5.14 ± 13.105 |
| DBP, Day 1: 24 hours, n=41, 40 | 4.07 ± 13.129 | 4.18 ± 11.569 |
| DBP, Day 29: pre-dialysis, n=38, 40 | 2.63 ± 14.749 | 5.88 ± 14.650 |
| DBP, Day 29: post dialysis, n=38, 40 | 0.18 ± 13.854 | 1.23 ± 12.259 |
| DBP, Day 57: pre-dialysis, n=32, 36 | 2.94 ± 13.457 | 5.86 ± 13.316 |
| DBP, Day 57: post dialysis, n=32, 36 | 1.72 ± 11.277 | 1.72 ± 12.230 |
| DBP, Day 57: 3 hours, n=32, 36 | 2.69 ± 17.087 | 4.89 ± 14.540 |
| DBP, Day 57: 12 hours, n=32, 36 | -2.38 ± 13.760 | 5.11 ± 14.186 |
| DBP, Day 57: 24 hours, n=32, 36 | 6.69 ± 15.995 | 3.97 ± 13.729 |
| DBP, Week 10: pre-dialysis, n=42, 42 | 3.71 ± 13.328 | 3.50 ± 12.975 |
| DBP, Week 10: post dialysis, n=41, 42 | 1.00 ± 10.151 | -2.81 ± 12.934 |
Temperature was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Degrees celsius | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Day 1: 3 hours, n=44, 43 | -0.027 ± 0.3744 | -0.067 ± 0.3220 |
| Day1: 12 hours, n=44, 43 | 0.016 ± 0.4011 | 0.065 ± 0.3981 |
| Day 1: 24 hours, n=41, 40 | 0.015 ± 0.3712 | -0.050 ± 0.3359 |
| Day 29: pre-dialysis, n=38, 40 | -0.089 ± 0.5451 | -0.033 ± 0.3731 |
| Day 29: post dialysis, n=38, 40 | -0.163 ± 0.4790 | -0.070 ± 0.4027 |
| Day 57: pre-dialysis, n=32, 36 | -0.003 ± 0.4447 | -0.028 ± 0.4158 |
| Day 57: post dialysis, n=32, 36 | -0.038 ± 0.3774 | -0.053 ± 0.3247 |
| Day 57: 3 hours, n=32, 36 | 0.000 ± 0.4048 | 0.067 ± 0.4697 |
| Day 57: 12 hours, n=32, 36 | 0.103 ± 0.5196 | -0.017 ± 0.3085 |
| Day 57: 24 hours, n=32, 36 | 0.025 ± 0.4501 | 0.075 ± 0.3557 |
| Week 10: pre-dialysis, n=42, 42 | -0.055 ± 0.4840 | -0.062 ± 0.4328 |
| Week 10: post dialysis, n=41, 42 | -0.002 ± 0.5270 | 0.005 ± 0.4311 |
Pulse rate was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.
| Beats per minute | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Day 1: 3 hours, n=44, 43 | 0.61 ± 7.735 | 0.02 ± 10.859 |
| Day1: 12 hours, n=44, 43 | 0.09 ± 8.232 | -3.53 ± 12.473 |
| Day 1: 24 hours, n=41, 40 | 1.39 ± 10.954 | -0.35 ± 11.005 |
| Day 29: pre-dialysis, n=38, 40 | 0.87 ± 9.393 | 0.03 ± 10.850 |
| Day 29: post dialysis, n=38, 40 | 1.95 ± 11.203 | 0.15 ± 12.593 |
| Day 57: pre-dialysis, n=32, 36 | 2.50 ± 10.522 | 2.14 ± 10.805 |
| Day 57: post dialysis, n=32, 36 | 0.53 ± 9.308 | 0.72 ± 12.523 |
| Day 57: 3 hours, n=32, 36 | -1.19 ± 11.998 | 0.22 ± 12.547 |
| Day 57: 12 hours, n=32, 36 | -1.59 ± 12.104 | 0.08 ± 10.811 |
| Day 57: 24 hours, n=32, 36 | -0.94 ± 11.435 | 0.33 ± 10.368 |
| Week 10: pre-dialysis, n=42, 42 | 1.33 ± 10.195 | -0.48 ± 13.457 |
| Week 10: post dialysis, n=41, 42 | -0.54 ± 9.344 | -1.74 ± 11.232 |
Collected over Non-SAEs were reported from start of study treatment and up to 8 weeks in treatment period and SAEs were reported from the start of the study treatment and up to 2 weeks in follow up period (Up to Week 10).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daprodustat | 0/45 (0%) | 10/45 (22.2%) | 10/45 (22.2%) |
| Recombinant Human Erythropoietin | 0/43 (0%) | 5/43 (11.6%) | 4/43 (9.3%) |
| Event | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| Fluid overloadMetabolism and nutrition disorders | 3/45 | 0/43 |
| Hypertensive urgencyVascular disorders | 2/45 | 0/43 |
| HypotensionVascular disorders | 2/45 | 0/43 |
| PneumoniaInfections and infestations | 2/45 | 0/43 |
| AnaemiaBlood and lymphatic system disorders | 2/45 | 0/43 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/45 | 1/43 |
| Abdominal painGastrointestinal disorders | 0/45 | 1/43 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/45 | 1/43 |
| Non-cardiac chest painGeneral disorders | 0/45 | 1/43 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/45 | 1/43 |
| Event | Daprodustat | Recombinant Human Erythropoietin |
|---|---|---|
| HeadacheNervous system disorders | 0/45 | 2/43 |
| HypertensionVascular disorders | 0/45 | 2/43 |
| Suspected COVID-19Infections and infestations | 0/45 | 1/43 |
| DiarrhoeaGastrointestinal disorders | 0/45 | 1/43 |
| NauseaGastrointestinal disorders | 0/45 | 1/43 |
| VomitingGastrointestinal disorders | 0/45 | 1/43 |
| AstheniaGeneral disorders | 0/45 | 1/43 |
| DizzinessNervous system disorders | 1/45 | 0/43 |
| ParaesthesiaNervous system disorders | 1/45 | 0/43 |
| PresyncopeNervous system disorders | 1/45 | 0/43 |
| Age, Continuous(Years) | Daprodustat | Recombinant Human Erythropoietin | Total |
|---|---|---|---|
| Mean | 60.9 ± 11.06 | 58.7 ± 10.61 | 59.8 ± 10.84 |
| Sex: Female, Male(Participants) | Daprodustat | Recombinant Human Erythropoietin | Total |
|---|---|---|---|
| Female | 19 | 16 | 35 |
| Male | 26 | 27 | 53 |
| Race/Ethnicity, Customized(Participants) | Daprodustat | Recombinant Human Erythropoietin | Total |
|---|---|---|---|
| Black or African American | 21 | 23 | 44 |
| White-Arabic/North African Heritage | 1 | 0 | 1 |
| White-White/Caucasian/European Heritage | 23 | 20 | 43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jul 2017 to primary completion in Jul 2020, 35 months.
Results were first posted in Jun 2021, 10 months after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 35 months is above that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863